1. Catalog
  2. GREPNSEM2503 - CME/CMLE - Equity of Biomarker Test ...
Image For Activity Cover
GREPNSEM2503 - CME/CMLE - Equity of Biomarker Testing in NSCLC
Course Description

Equity of Biomarker Testing in NSCLC     

Activity Description: 

This interactive microlearning activity is part of a case-based series designed to engage pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in improving biomarker testing and treatment for NSCLC. This specific course focuses on equity in biomarker testing and the challenges to implementing biomarker testing in the clinical workflow. 

Course topics include:  

  • EGFR mutations 

  • Ultra-stat testing 

  • Challenges in implementing biomarker testing 

 
Target Audience

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.    


Faculty/Authors

Diana Ionescu, M.D.
Professor, Clinical Pathology
University of British Columbia, Vancouver, Canada 

Physician Competencies:  
Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement  

Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this activity for a maximum of .25 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided online.  

Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. 


Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures 

Technical Considerations 

Release Dates: 2/3/2025         
Review Date:
Expiration Date: 2/3/2028    




Course Objectives

Upon completion of this activity, you will be able 
 

  • Understand the role of molecular biomarker testing in guiding targeted therapy decisions for lung cancer patients 

  • Explain the importance of timely biomarker testing and its impact on treatment initiation 

  • Recognize clinical and demographic factors that influence the likelihood of specific biomarker mutations in NSCLC 

  • Analyze common challenges and barriers to implementing biomarker testing in clinical workflow 

Summary
Availability: On-Demand
Credit Offered:
0.25 CME/CMLE Credit
Powered By